Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone805-418-5006
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
Next Earnings DateN/A
OptionableNot Optionable
I-Mab (NASDAQ:ARQT) Frequently Asked Questions
What is I-Mab's stock symbol?
I-Mab trades on the NASDAQ under the ticker symbol "ARQT."
What price target have analysts set for ARQT?
4 brokerages have issued 12-month target prices for I-Mab's stock. Their forecasts range from $30.00 to $55.00. On average, they anticipate I-Mab's stock price to reach $42.75 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price. View Analyst Price Targets for I-Mab.
What is the consensus analysts' recommendation for I-Mab?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for I-Mab.
Has I-Mab been receiving favorable news coverage?
Headlines about ARQT stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. I-Mab earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for I-Mab.
Who are some of I-Mab's key competitors?
Some companies that are related to I-Mab include FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), PPD (SDGR), Zai Lab (ZLAB), Alkermes (ALKS), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE) and Genmab A/S (GMAB).
What other stocks do shareholders of I-Mab own?
Who are I-Mab's key executives?
I-Mab's management team includes the folowing people:
- Mr. Todd Franklin Watanabe, Pres, CEO & Director (Age 51)
- Dr. Bhaskar Chaudhuri, Co-Founder & Independent Director (Age 65)
- Mr. John W. Smither, Chief Financial Officer (Age 67)
- Dr. David W. Osborne, Chief Technical Officer (Age 59)
- Mr. Keith L. Klein, Gen. Counsel & Sec. (Age 56)
When did I-Mab IPO?
(ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.
When does the company's quiet period expire?
I-Mab's quiet period expires on Wednesday, March 11th. I-Mab had issued 9,375,000 shares in its initial public offering on January 31st. The total size of the offering was $159,375,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of I-Mab?
Shares of ARQT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is I-Mab's stock price today?
One share of ARQT stock can currently be purchased for approximately $28.54.
How big of a company is I-Mab?
What is I-Mab's official website?
How can I contact I-Mab?
I-Mab's mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company can be reached via phone at 805-418-5006 or via email at [email protected]
MarketBeat Community Rating for I-Mab (NASDAQ ARQT)
MarketBeat's community ratings are surveys of what our community members think about I-Mab and other stocks. Vote "Outperform" if you believe ARQT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQT will underperform the S&P 500 over the long term. You may vote once every thirty days.
